ALHF II has completed its third closing in collaboration with a leading U.S.

Texas-based life science venture studio.

Aug 23, 2024 - We are pleased to announce that Axil Life Science & Healthcare Fund II L.P. (“ALHF II”) has secured the participation of the corporate sponsor of Fannin Innovation (“Fannin”), the most active early stage life science product development firm in Texas. Additionally, ALHF II received an increased commitment from the Organization for Small & Medium Enterprises and Regional Innovation, JAPAN.
 
Fannin is a product development firm that in-licenses and internally develops early stage biotech and medtech products from scientific insight to and through the clinic. Based in Houston, Fannin sources ideas globally and talent locally from the largest medical center in the world, home to more than 50 health care institutions including MD Anderson Cancer Center and Baylor College of Medicine. The strategic partnership with Fannin marks a significant milestone in ALHF II’s growth, enhancing its ability to invest in transformative biotech solutions while fostering cross-border collaboration between Japan and the U.S.

For more information on Fannin, please see https:  https://www.fannininnovation.com/